Investment analysis and updates encompass potential shifts in AMGN Amgen's stock value, alongside anticipations and adjustments to its research and development priorities. The prominent biotech entity had varied financial coverage, as National Pension Service continues with a $334.14 million stock position, while AE Wealth Management LLC bought 18,798 shares and Mirae Asset Global Investments Co. Ltd. secured 47,958 more shares. However, it witnessed a slowdown from New York State Common Retirement Fund and Bank of New York Mellon Corp that sold their shares, and Intact Investment Management Inc. reduced its stock position. HSBC and Oppenheimer maintained a bullish outlook on the entity's future out to 2026. Furthermore, AMGN reported Q3 earnings, and despite projected earnings decline, the company's valuation has continued to draw attention from investors. AMGN also ended its collaboration with Kyowa Kirin turning towards GLP-1 therapies for obesity management while acquiring Dark Blue Therapeutics to widen their oncology pipeline. Still, the termination of licensing and collaboration arrangements carries implications for stakeholders. Innovations continue, with AMGN announcing an investment exceeding $500 million in a state-of-the-art Science and Innovation Center, which is perceived as progressive.
Amgen AMGN News Analytics from Fri, 18 Jul 2025 07:00:00 GMT to Sat, 31 Jan 2026 08:51:21 GMT -
Rating 2
- Innovation 7
- Information 8
- Rumor 5
